Ardelyx (ARDX) Stock Price, News & Analysis

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.

9 analysts have issued 1-year price targets for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they predict the company's stock price to reach $12.69 in the next twelve months. This suggests a possible upside of 97.0% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.

Ardelyx's stock was trading at $6.20 at the beginning of the year. Since then, ARDX shares have increased by 3.9% and is now trading at $6.44.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARDX earnings forecast.

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. The biopharmaceutical company had revenue of $34.36 million for the quarter, compared to the consensus estimate of $34.26 million. Ardelyx had a negative trailing twelve-month return on equity of 43.57% and a negative net margin of 53.08%. The company's quarterly revenue was down 22.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.06 earnings per share.

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Inspire Small/Mid Cap ETF (ISMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.19%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.